

# Coronavirus disease 2019 (COVID-19)

## Situation Report – 83

Data as received by WHO from national authorities by 10:00 CET, 12 April 2020

### HIGHLIGHTS

- No new country/territory/area reported cases of COVID-19 in the past 24 hours.
- The total global deaths from COVID-19 has surpassed 100 000.
- WHO has published a document 'Target Product Profiles for COVID-19 Vaccines'. The document describes the preferred and minimally acceptable profiles for human vaccines for long term protection of persons at high ongoing risk of COVID-19, such as healthcare workers, and for reactive use in outbreak settings. For more details, please see [here](#).

### SITUATION IN NUMBERS

total (new cases in last 24 hours)

#### Globally

1 696 588 confirmed (85 679)

105 952 deaths (6262)

#### European Region

880 106 confirmed (40 849)

74 237 deaths (3672)

#### Region of the Americas

573 940 confirmed (37 276)

21 531 deaths (2237)

#### Western Pacific Region

120 116 confirmed (1567)

4058 deaths (41)

#### Eastern Mediterranean Region

95 945 confirmed (3719)

4943 deaths (172)

#### South-East Asia Region

16 041 confirmed (1880)

728 deaths (111)

#### African Region


9728 confirmed (388)

444 deaths (29)

#### WHO RISK ASSESSMENT

Global Level Very High

Figure 1. Countries, territories or areas with reported confirmed cases of COVID-19, 12 April 2020



## SURVEILLANCE

**Table 1. Countries, territories or areas with reported laboratory-confirmed COVID-19 cases and deaths. Data as of 12 April 2020\***

Reporting Country/ Territory/Area <sup>†</sup>	Total confirmed ‡ cases	Total confirmed new cases	Total deaths	Total new deaths	Transmission classification <sup>§</sup>	Days since last reported case
<b>Western Pacific Region</b>						
China	83482	113	3349	0	Clusters of cases	0
Republic of Korea	10512	32	214	3	Clusters of cases	0
Japan	6748	743	98	4	Clusters of cases	0
Australia	6289	51	57	3	Clusters of cases	0
Malaysia	4530	184	73	3	Clusters of cases	0
Philippines	4428	233	247	26	Clusters of cases	0
Singapore	2299	191	8	1	Clusters of cases	0
New Zealand	1049	14	4	0	Sporadic Cases	0
Viet Nam	258	1	0	0	Clusters of cases	0
Brunei Darussalam	136	0	1	0	Sporadic Cases	1
Cambodia	122	2	0	0	Sporadic Cases	0
Fiji	16	0	0	0	Sporadic Cases	1
Lao People's Democratic Republic	16	0	0	0	Sporadic Cases	1
Mongolia	16	0	0	0	Sporadic Cases	3
Papua New Guinea	2	0	0	0	Sporadic Cases	3
<b>Territories**</b>						
Guam	133	3	5	1	Clusters of cases	0
French Polynesia	51	0	0	0	Sporadic Cases	3
New Caledonia	18	0	0	0	Sporadic Cases	9
Northern Mariana Islands (Commonwealth of the)	11	0	2	0	Pending	3
<b>European Region</b>						
Spain	161852	4830	16353	510	Pending	0
Italy	152271	4694	19470	619	Pending	0
Germany	120479	2821	2673	129	Pending	0
France	92787	3104	13814	635	Pending	0
The United Kingdom	78995	8719	9875	917	Pending	0
Turkey	52167	5138	1101	95	Community Transmission	0
Belgium	28018	1351	3346	327	Pending	0
Switzerland	24820	592	831	26	Community Transmission	0
Netherlands	24413	1316	2643	132	Pending	0
Portugal	15987	515	470	35	Pending	0
Russian Federation	15770	2186	130	24	Clusters of cases	0
Austria	13807	247	337	18	Pending	0
Israel	10525	430	96	4	Pending	0
Sweden	10151	466	887	17	Pending	0

Ireland	8928	839	320	33	Pending	0
Poland	6356	401	208	27	Pending	0
Norway	6320	76	98	6	Pending	0
Denmark	5996	177	260	13	Pending	0
Romania	5990	523	282	25	Pending	0
Czechia	5902	170	129	10	Pending	0
Serbia	3380	275	74	3	Pending	0
Luxembourg	3270	47	62	8	Pending	0
Finland	2905	136	49	1	Pending	0
Ukraine	2777	266	83	10	Clusters of cases	0
Belarus	2226	245	23	4	Clusters of cases	0
Greece	2081	70	93	3	Pending	0
Iceland	1689	14	8	1	Pending	0
Republic of Moldova	1560	122	30	1	Pending	0
Croatia	1534	39	21	0	Pending	0
Hungary	1410	100	99	14	Pending	0
Estonia	1304	46	24	0	Pending	0
Slovenia	1188	28	50	5	Pending	0
Azerbaijan	1058	67	11	1	Clusters of cases	0
Lithuania	1053	54	23	6	Pending	0
Armenia	1013	76	13	2	Clusters of cases	0
Bosnia and Herzegovina	948	47	37	0	Community Transmission	0
Kazakhstan	897	38	10	0	Pending	0
North Macedonia	828	117	34	2	Clusters of cases	0
Uzbekistan	796	172	3	0	Clusters of cases	0
Slovakia	728	13	2	0	Pending	0
Bulgaria	661	26	28	3	Pending	0
Latvia	630	18	3	1	Pending	0
Andorra	622	20	28	2	Community Transmission	0
Cyprus	616	21	15	0	Pending	0
Albania	446	30	23	0	Clusters of cases	0
Kyrgyzstan	377	38	5	0	Pending	0
Malta	370	20	3	1	Pending	0
San Marino	356	12	35	1	Community Transmission	0
Montenegro	262	7	2	0	Clusters of cases	0
Georgia	252	19	3	0	Clusters of cases	0
Liechtenstein	80	0	1	0	Pending	1
Monaco	54	0	0	0	Sporadic Cases	3
Holy See	8	0	0	0	Sporadic Cases	3
Territories **						
Kosovo <sup>[1]</sup>	283	33	7	0	Community Transmission	0
Isle of Man	204	14	1	0	Pending	0
Guernsey	200	9	6	1	Pending	0
Jersey	198	15	4	0	Pending	0
Faroe Islands	184	0	0	0	Pending	4
Gibraltar	113	0	1	0	Pending	4

Greenland	11	0	0	0	Pending	6
<b>South-East Asia Region</b>						
India	8356	909	273	34	Clusters of cases	0
Indonesia	4241	729	373	67	Clusters of cases	0
Thailand	2551	33	38	3	Clusters of cases	0
Bangladesh	621	197	34	7	Clusters of cases	0
Sri Lanka	199	2	7	0	Clusters of cases	0
Myanmar	38	10	3	0	Clusters of cases	0
Maldives	19	0	0	0	Clusters of cases	9
Nepal	9	0	0	0	Sporadic Cases	7
Bhutan	5	0	0	0	Sporadic Cases	9
Timor-Leste	2	0	0	0	Sporadic Cases	1
<b>Eastern Mediterranean Region</b>						
Iran (Islamic Republic of)	70029	1837	4357	125	Community Transmission	0
Pakistan	5038	250	86	15	Clusters of cases	0
Saudi Arabia	4033	382	52	5	Clusters of cases	0
United Arab Emirates	3736	376	20	4	Pending	0
Qatar	2728	216	6	0	Pending	0
Egypt	1939	145	146	11	Clusters of cases	0
Morocco	1545	97	111	4	Clusters of cases	0
Iraq	1318	38	72	1	Clusters of cases	0
Kuwait	1154	161	1	0	Clusters of cases	0
Bahrain	1040	42	6	0	Clusters of cases	0
Tunisia	685	14	28	3	Community Transmission	0
Lebanon	619	10	20	0	Clusters of cases	0
Oman	599	53	3	0	Clusters of cases	0
Afghanistan	555	34	18	3	Clusters of cases	0
Jordan	381	9	7	0	Clusters of cases	0
Djibouti	187	37	2	1	Clusters of cases	0
Libya	25	1	1	0	Clusters of cases	0
Syrian Arab Republic	25	6	2	0	Community Transmission	0
Somalia	21	9	1	0	Sporadic Cases	0
Sudan	19	2	2	0	Sporadic Cases	0
Yemen	1	0	0	0	Pending	1
<b>Territories**</b>						
occupied Palestinian territory	268	0	2	0	Clusters of cases	1
<b>Region of the Americas</b>						
United States of America	492881	31606	18516	1920	Community Transmission	0
Canada	22544	1318	600	69	Community Transmission	0
Brazil	19638	1781	1056	115	Community Transmission	0
Ecuador	7257	96	315	18	Community Transmission	0
Chile	6927	426	73	8	Community Transmission	0

Peru	5897	641	169	31	Community Transmission	0
Mexico	3844	403	233	39	Community Transmission	0
Panama	2974	222	74	8	Community Transmission	0
Dominican Republic	2620	271	126	8	Community Transmission	0
Colombia	2473	250	80	11	Community Transmission	0
Argentina	1975	46	82	3	Community Transmission	0
Cuba	620	56	16	1	Clusters of cases	0
Costa Rica	558	19	3	0	Clusters of cases	0
Uruguay	494	21	7	0	Clusters of cases	0
Honduras	392	10	24	1	Clusters of cases	0
Bolivia (Plurinational State of)	275	7	20	1	Clusters of cases	0
Venezuela (Bolivarian Republic of)	171	0	9	0	Clusters of cases	1
Guatemala	137	11	3	0	Clusters of cases	0
Paraguay	133	4	6	0	Clusters of cases	0
El Salvador	118	1	6	0	Clusters of cases	0
Trinidad and Tobago	109	0	8	0	Clusters of cases	2
Barbados	67	1	4	0	Clusters of cases	0
Jamaica	65	2	4	0	Clusters of cases	0
Bahamas	42	1	8	0	Clusters of cases	0
Guyana	37	0	6	0	Clusters of cases	2
Haiti	31	1	2	0	Clusters of cases	0
Antigua and Barbuda	21	2	2	0	Clusters of cases	0
Dominica	16	0	0	0	Clusters of cases	1
Saint Lucia	15	1	0	0	Sporadic Cases	0
Grenada	14	2	0	0	Clusters of cases	0
Saint Kitts and Nevis	12	1	0	0	Sporadic Cases	0
Saint Vincent and the Grenadines	12	0	0	0	Sporadic Cases	1
Belize	10	0	2	1	Sporadic Cases	1
Suriname	10	0	1	0	Sporadic Cases	8
Nicaragua	7	0	1	0	Pending	1
<b>Territories**</b>						
Puerto Rico	788	63	42	3	Clusters of cases	0
Martinique	155	1	6	0	Clusters of cases	0
Guadeloupe	143	0	8	0	Clusters of cases	1
Aruba	92	6	0	0	Clusters of cases	0
French Guiana	86	2	0	0	Clusters of cases	0
United States Virgin Islands	53	3	1	0	Clusters of cases	0
Sint Maarten	50	0	9	0	Sporadic Cases	1
Bermuda	48	0	4	0	Clusters of cases	1
Cayman Islands	45	0	1	0	Clusters of cases	3
Saint Martin	33	1	2	0	Sporadic Cases	0

Curaçao	14	0	1	0	Sporadic Cases	3
Montserrat	9	0	0	0	Sporadic Cases	1
Turks and Caicos Islands	8	0	1	0	Sporadic Cases	4
Saint Barthelemy	6	0	0	0	Sporadic Cases	12
Falkland Islands (Malvinas)	5	0	0	0	Sporadic Cases	3
Anguilla	3	0	0	0	Sporadic Cases	8
British Virgin Islands	3	0	0	0	Sporadic Cases	11
Bonaire, Sint Eustatius and Saba	2	0	0	0	Sporadic Cases	8
Saint Pierre and Miquelon	1	0	0	0	Sporadic Cases	4
<b>African Region</b>						
South Africa	2028	25	25	1	Community Transmission	0
Algeria	1825	64	275	19	Community Transmission	0
Cameroon	803	0	10	0	Clusters of cases	1
Côte d'Ivoire	533	53	4	1	Clusters of cases	0
Niger	491	53	11	0	Clusters of cases	0
Burkina Faso	443	0	19	0	Clusters of cases	1
Ghana	408	30	8	2	Clusters of cases	0
Mauritius	319	1	9	0	Clusters of cases	0
Nigeria	318	13	10	3	Clusters of cases	0
Senegal	278	13	2	0	Clusters of cases	0
Guinea	250	56	0	0	Clusters of cases	0
Democratic Republic of the Congo	223	8	20	0	Clusters of cases	0
Kenya	191	2	7	0	Clusters of cases	0
Rwanda	120	2	0	0	Sporadic Cases	0
Madagascar	104	9	0	0	Clusters of cases	0
Mali	87	13	7	0	Sporadic Cases	0
Togo	73	0	3	0	Sporadic Cases	2
Ethiopia	69	4	3	1	Sporadic Cases	0
Congo	60	0	5	0	Clusters of cases	3
Uganda	53	0	0	0	Sporadic Cases	3
Gabon	49	5	1	0	Sporadic Cases	0
Liberia	48	11	5	0	Sporadic Cases	0
Zambia	40	0	2	0	Sporadic Cases	1
Guinea-Bissau	38	3	0	0	Sporadic Cases	0
Benin	35	5	2	1	Sporadic Cases	0
Eritrea	33	0	0	0	Sporadic Cases	3
United Republic of Tanzania	32	0	3	0	Sporadic Cases	1
Mozambique	20	0	0	0	Sporadic Cases	1
Angola	19	0	2	0	Sporadic Cases	3
Equatorial Guinea	18	0	0	0	Sporadic Cases	2
Namibia	16	0	0	0	Sporadic Cases	6
Botswana	13	0	1	0	Sporadic Cases	2
Zimbabwe	13	2	3	0	Sporadic Cases	0

Eswatini	12	0	0	0	Sporadic Cases	3
Malawi	12	3	2	1	Sporadic Cases	0
Central African Republic	11	0	0	0	Sporadic Cases	1
Chad	11	0	0	0	Sporadic Cases	2
Seychelles	11	0	0	0	Sporadic Cases	5
Gambia	9	5	1	0	Sporadic Cases	0
Sierra Leone	8	1	0	0	Sporadic Cases	0
Cabo Verde	7	0	1	0	Sporadic Cases	5
Mauritania	7	0	1	0	Sporadic Cases	1
São Tomé and Príncipe	4	0	0	0	Pending	5
South Sudan	4	1	0	0	Pending	0
Burundi	3	0	0	0	Sporadic Cases	8
<b>Territories**</b>						
Réunion	388	6	0	0	Clusters of cases	0
Mayotte	191	0	2	0	Clusters of cases	2
<b>Subtotal for all Regions</b>	<b>1695876</b>	<b>85679</b>	<b>105941</b>	<b>6262</b>		
International conveyance (Diamond Princess)	712	0	11	0	Not Applicable <sup>††</sup>	27
<b>Grand total</b>	<b>1696588</b>	<b>85679</b>	<b>105952</b>	<b>6262</b>		

\*Numbers include both domestic and repatriated cases

†The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

‡Case classifications are based on [WHO case definitions](#) for COVID-19.

§Transmission classification is based on a process of country/territory/area self-reporting. Classifications are reviewed on a weekly basis and may be upgraded or downgraded as new information becomes available. Not all locations within a given country/territory/area are equally affected; countries/territories/areas experiencing multiple types of transmission are classified in the highest category reported. Within a given transmission category, different countries/territories/areas may have differing degrees of transmission as indicated by the differing numbers of cases, recency of cases, and other factors.

Terms:

- **No cases:** Countries/territories/areas with no confirmed cases (not shown in table)
- **Sporadic cases:** Countries/territories/areas with one or more cases, imported or locally detected
- **Clusters of cases:** Countries/territories/areas experiencing cases, clustered in time, geographic location and/or by common exposures
- **Community transmission:** Countries/area/territories experiencing larger outbreaks of local transmission defined through an assessment of factors including, but not limited to:
  - Large numbers of cases not linkable to transmission chains
  - Large numbers of cases from sentinel lab surveillance
  - Multiple unrelated clusters in several areas of the country/territory/area


\*\* "Territories" include territories, areas, overseas dependencies and other jurisdictions of similar status

[1] All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

†† As the international conveyance (Diamond Princess) is no longer occupied, transmission classification cannot be applied.

Due to differences in reporting methods, retrospective data consolidation, and reporting delays, the number of new cases may not always reflect the exact difference between yesterday's and today's totals. WHO COVID-19 Situation Reports present official counts of confirmed COVID-19 cases, thus differences between WHO reports and other sources of COVID-19 data using different inclusion criteria and different data cutoff times are to be expected.

**Figure 1. Epidemic curve of confirmed COVID-19, by date of report and WHO region through 12 April 2020**



## STRATEGIC OBJECTIVES

WHO's strategic objectives for this response are to:

- Interrupt human-to-human transmission including reducing secondary infections among close contacts and health care workers, preventing transmission amplification events, and preventing further international spread\*;
- Identify, isolate and care for patients early, including providing optimized care for infected patients;
- Identify and reduce transmission from the animal source;
- Address crucial unknowns regarding clinical severity, extent of transmission and infection, treatment options, and accelerate the development of diagnostics, therapeutics and vaccines;
- Communicate critical risk and event information to all communities and counter misinformation;
- Minimize social and economic impact through multisectoral partnerships.

\*This can be achieved through a combination of public health measures, such as rapid identification, diagnosis and management of the cases, identification and follow up of the contacts, infection prevention and control in health care settings, implementation of health measures for travelers, awareness-raising in the population and risk communication.



## PREPAREDNESS AND RESPONSE

- To view all technical guidance documents regarding COVID-19, please go to [this webpage](#).
- WHO has developed interim guidance for laboratory diagnosis, advice on the use of masks during home care and in health care settings in the context of COVID-19 outbreak, clinical management, infection prevention and control in health care settings, home care for patients with suspected novel coronavirus, risk communication and community engagement and Global Surveillance for human infection with COVID-19.
- WHO is working closely with International Air Transport Association (IATA) and have jointly developed a guidance document to provide advice to cabin crew and airport workers, based on country queries. The guidance can be found on the [IATA webpage](#).
- WHO has been in regular and direct contact with Member States where cases have been reported. WHO is also informing other countries about the situation and providing support as requested.
- WHO is working with its networks of researchers and other experts to coordinate global work on surveillance, epidemiology, mathematical modelling, diagnostics and virology, clinical care and treatment, infection prevention and control, and risk communication. WHO has issued interim guidance for countries, which are updated regularly.
- WHO has prepared a [disease commodity package](#) that includes an essential list of biomedical equipment, medicines and supplies necessary to care for patients with COVID-19.
- WHO has provided recommendations to reduce risk of [transmission from animals to humans](#).
- WHO has published an [updated recommendations for international traffic in relation to COVID-19 outbreak](#).
- WHO has activated the R&D blueprint to accelerate diagnostics, vaccines, and therapeutics.
- OpenWHO is an interactive, web-based, knowledge-transfer platform offering online courses to improve the response to health emergencies. [COVID-19 courses can be found here](#) and courses in [additional national languages here](#). Specifically, WHO has developed online courses on the following topics:
  - Introduction to Go.Data – Field data collection, chains of transmission and contact follow-up. The Go.Data tool is available globally to WHO staff, member states and partners to support outbreak investigation, focusing on field data collection, contact tracing and visualisation of chains of transmission.
  - A general introduction to emerging respiratory viruses, including novel coronaviruses (available in Arabic, Chinese, English, French, Russian, Spanish, Hindi, Indian Sign Language, Persian, Portuguese, Serbian and Turkish);
  - Clinical care for Severe Acute Respiratory Infections (available in English, French, Russian, Indonesian and Vietnamese);
  - Health and safety briefing for respiratory diseases - ePROTECT (available in Chinese, English, French, Russian, Spanish, Indonesian and Portuguese);
  - Infection Prevention and Control for Novel Coronavirus (COVID-19) (available in Chinese, English, French, Russian, Spanish, Indonesian, Italian, Japanese, Portuguese and Serbian); and
  - COVID-19 Operational Planning Guidelines and COVID-19 Partners Platform to support country preparedness and response (available in English and coming soon in additional languages).
- WHO is providing guidance on early investigations, which are critical in an outbreak of a new virus. The data collected from the protocols can be used to refine recommendations for surveillance and case definitions, to characterize the key epidemiological transmission features of COVID-19, help understand spread, severity, spectrum of disease, impact on the community and to inform operational models for implementation of countermeasures such as case isolation, contact tracing and isolation. Several protocols are available [here](#). One such protocol is for the investigation of early COVID-19 cases and contacts (the [“First Few X \(FFX\) Cases and contact investigation protocol for 2019-novel coronavirus \(2019-nCoV\) infection”](#)). The protocol is designed to gain an early understanding of the key clinical, epidemiological and virological characteristics of the first cases of COVID-19 infection detected in any individual country, to inform the development and updating of public health guidance to manage cases and reduce the potential spread and impact of infection.

## RECOMMENDATIONS AND ADVICE FOR THE PUBLIC

If you are not in an area where COVID-19 is spreading or have not travelled from an area where COVID-19 is spreading or have not been in contact with an infected patient, your risk of infection is low. It is understandable that you may feel anxious about the outbreak. Get the facts from reliable sources to help you accurately determine your risks so that you can take reasonable precautions (see [Frequently Asked Questions](#)). Seek guidance from WHO, your healthcare provider, your national public health authority or your employer for accurate information on COVID-19 and whether COVID-19 is circulating where you live. It is important to be informed of the situation and take appropriate measures to protect yourself and your family (see [Protection measures for everyone](#)).

If you are in an area where there are cases of COVID-19 you need to take the risk of infection seriously. Follow the advice of WHO and guidance issued by national and local health authorities. For most people, COVID-19 infection will cause mild illness however, it can make some people very ill and, in some people, it can be fatal. Older people, and those with pre-existing medical conditions (such as cardiovascular disease, chronic respiratory disease or diabetes) are at risk for severe disease (See [Protection measures for persons who are in or have recently visited \(past 14 days\) areas where COVID-19 is spreading](#)).

## CASE DEFINITIONS

WHO periodically updates the [Global Surveillance for human infection with coronavirus disease \(COVID-19\)](#) document which includes case definitions.

For easy reference, case definitions are included below.

### Suspect case

- A. A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath), AND a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset.

**OR**

- B. A patient with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-19 case (see definition of contact) in the last 14 days prior to symptom onset;

**OR**

- C. A patient with severe acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath; AND requiring hospitalization) AND in the absence of an alternative diagnosis that fully explains the clinical presentation.

### Probable case

- A. A suspect case for whom testing for the COVID-19 virus is inconclusive.  
a. Inconclusive being the result of the test reported by the laboratory.

**OR**

- B. A suspect case for whom testing could not be performed for any reason.

### Confirmed case

A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.

- Technical guidance for laboratory testing can be found [here](#).

### Definition of contact

A contact is a person who experienced any one of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a probable or confirmed case:

1. Face-to-face contact with a probable or confirmed case within 1 meter and for more than 15 minutes;
2. Direct physical contact with a probable or confirmed case;
3. Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment<sup>1</sup>; OR
4. Other situations as indicated by local risk assessments.

Note: for confirmed asymptomatic cases, the period of contact is measured as the 2 days before through the 14 days *after the date on which the sample was taken* which led to confirmation.

---

<sup>1</sup> World Health Organization. Infection prevention and control during health care when COVID-19 is suspected  
[https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-\(ncov\)-infection-is-suspected-20200125](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125)